GLOPERBA Drug Patent Profile
✉ Email this page to a colleague
When do Gloperba patents expire, and what generic alternatives are available?
Gloperba is a drug marketed by Scilex Pharms and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has three patent family members in two countries.
The generic ingredient in GLOPERBA is colchicine. There are sixteen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the colchicine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gloperba
A generic version of GLOPERBA was approved as colchicine by AMNEAL PHARMS on September 28th, 2016.
Summary for GLOPERBA
| International Patents: | 3 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 113 |
| Clinical Trials: | 1 |
| Patent Applications: | 1,201 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for GLOPERBA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for GLOPERBA |
| What excipients (inactive ingredients) are in GLOPERBA? | GLOPERBA excipients list |
| DailyMed Link: | GLOPERBA at DailyMed |
Recent Clinical Trials for GLOPERBA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Helwan University | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for GLOPERBA
Paragraph IV (Patent) Challenges for GLOPERBA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| GLOPERBA | Oral Solution | colchicine | 0.6 mg/5 mL | 210942 | 1 | 2020-04-02 |
US Patents and Regulatory Information for GLOPERBA
GLOPERBA is protected by four US patents.
Patents protecting GLOPERBA
Colchicine drug-to-drug interactions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Colchicine drug-to-drug interactions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD OF PROPHYLACTIC TREATMENT OF GOUT FLARES IN ADULTS COMPRISES ADMINISTERING TO A PATIENT A LIQUID COLCHICINE ORAL SOLUTION
Colchicine drug-to-drug interactions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Composition and method of use of colchicine oral liquid
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scilex Pharms | GLOPERBA | colchicine | SOLUTION;ORAL | 210942-001 | Jan 30, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Scilex Pharms | GLOPERBA | colchicine | SOLUTION;ORAL | 210942-001 | Jan 30, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Scilex Pharms | GLOPERBA | colchicine | SOLUTION;ORAL | 210942-001 | Jan 30, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Scilex Pharms | GLOPERBA | colchicine | SOLUTION;ORAL | 210942-001 | Jan 30, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for GLOPERBA
See the table below for patents covering GLOPERBA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 3426227 | COMPOSITION ET MÉTHODE D'UTILISATION DE LIQUIDE ORAL DE COLCHICINE (COMPOSITION AND METHOD OF USE OF COLCHICINE ORAL LIQUID) | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2017156392 | ⤷ Try a Trial | |
| World Intellectual Property Organization (WIPO) | 2019126579 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
